Jiangsu Maiweikang New Drug R & D Co Ltd

To evaluate the efficacy, safety, and immunogenicity of 9MW2821 combined with toripalimab versus standard chemotherapy as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma.

Primary objective: To evaluate the preliminary efficacy of 9MW2821 alone or in combination with PD-1 monoclonal antibody in patients with locally advanced or metastatic triple-negative breast cancer;

Comparison of progression-free survival and overall survival between 9MW2821 and investigator's choice of chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who have received prior treatment with platinum-containing chemotherapy and a PD-(L)1 inhibitor